New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2013
10:03 EDTDELL, LULU, FISV, UAL, AMTD, AXP, BHP, SYA, VRTX, WSO, SSRI, PFG, LOGI, AFL, RKT, PDCO, DY, ARMH, SIRO, REGN, PAAS, BIIBOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ARM Holdings (ARMH) downgraded to Equal Weight from Overweight at Morgan Stanley... Aflac (AFL) downgraded to Neutral from Buy at Sterne Agee... Biogen (BIIB) downgraded to Neutral from Buy at BofA/Merrill... Dycom (DY) downgraded to Outperform from Strong Buy at Raymond James... Logitech (LOGI) downgraded to Underperform from Neutral at Credit Suisse... Pan American Silver (PAAS) downgraded to Hold from Buy at Deutsche Bank... Patterson Companies (PDCO) downgraded to Sell from Neutral at Goldman... Principal Financial (PFG) downgraded to Neutral from Buy at Sterne Agee... Regeneron (REGN) downgraded to Hold from Buy at Jefferies... Rock-Tenn (RKT) downgraded to Buy from Conviction Buy at Goldman... Silver Standard (SSRI) downgraded to Sell from Hold at Deutsche Bank... Sirona Dental (SIRO) downgraded to Neutral from Buy at Goldman... Symetra Financial (SYA) downgraded to Underperform from Neutral at Sterne Agee... TD Ameritrade (AMTD) downgraded to Neutral from Buy at Sterne Agee... Watsco (WSO) downgraded to Neutral from Outperform at RW Baird... BHP Billiton (BHP) downgraded to Hold from Buy at Dahlman Rose... United Continental (UAL) downgraded to Neutral from Overweight at JPMorgan... Vertex (VRTX) downgraded to Neutral from Buy at Lazard Capital... American Express (AXP) downgraded to Underweight from Neutral at JPMorgan... Fiserv (FISV) downgraded to Equal Weight from Overweight at First Analysis... lululemon (LULU) downgraded to Underperform from Neutral at Buckingham... Dell (DELL)downgraded to Neutral from Buy at Monness Crespi.
News For ARMH;AFL;BIIB;DY;LOGI;PAAS;PDCO;PFG;REGN;RKT;SSRI;SIRO;SYA;AMTD;WSO;BHP;UAL;VRTX;AXP;FISV;LULU;DELL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
March 18, 2015
12:48 EDTBIIBFly Watch: Biogen predicted to report strong Alzheimer's data this Friday
Subscribe for More Information
10:48 EDTARMHCadence, ARM announce strategic IP interoperability agreement
Subscribe for More Information
07:34 EDTBIIBBiogen should report strong Alzheimer's data, says RBC Capital
Subscribe for More Information
07:18 EDTAMTDWells Fargo to hold a forum
Subscribe for More Information
07:16 EDTSYAJPMorgan to hold a conference
Subscribe for More Information
06:16 EDTAXPAmerican Express to launch Plenti loyalty program this spring, WSJ reports
Subscribe for More Information
March 17, 2015
13:14 EDTBHPBHP Billiton upgraded to Buy from Neutral at Citigroup
10:49 EDTPDCOPatterson Companies raises quarterly dividend 10% to 22c per share
Subscribe for More Information
10:00 EDTSIROOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:06 EDTUALBoeing delivers first 787-9 Dreamliner assembled at North Charleston facility
Subscribe for More Information
07:45 EDTSIROSirona Dental downgraded to Market Perform from Outperform at William Blair
Subscribe for More Information
05:51 EDTBHPBHP Billiton's South32 demerger to cost $738M
Subscribe for More Information
March 16, 2015
12:01 EDTAXPAmerican Express reports February net write-off rate 1.5% vs. 1.4% last month
Reports February 30 days past due loans 1.0% vs. 1.0% last month.
10:02 EDTBHPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:07 EDTBHPBHP Billiton downgraded to Neutral from Overweight at HSBC
Subscribe for More Information
09:03 EDTFISVFiserv solutions selected by FSBNW
Subscribe for More Information
08:23 EDTREGNPCSK9 data continues to impress, says Leerink
Subscribe for More Information
07:16 EDTREGNRegeneron Sanofi dupilumab drug can generate $6B+ in revenue, says Bernstein
Bernstein believes that dupilumab, a drug made by Regeneron and Sanofi, has shown strong efficacy in patients with severe atopic dermatitis. The firm notes that the drug is currently in pivotal trials involving patients with severe levels of other common diseases. The firm thinks the drug can generate $1.5B of revenue by 2018 and $3.8B by 2020. Bernstein keeps a $500 price target and Outperform rating on Regeneron.
06:40 EDTREGNPCSK9 studies show potential improvement in heart health, WSJ says
Subscribe for More Information
March 15, 2015
13:04 EDTREGNSanofi, Regeneron announce publication of results of ODYSSEY long term trial
Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) today announced that 18-month results of a Phase 3 trial of Praluent, alirocumab, an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published online in The New England Journal of Medicine. In the ODYSSEY LONG TERM trial, Praluent 150 mg every two weeks reduced low-density lipoprotein cholesterol by an additional 62% at week 24 when compared to placebo, the primary efficacy endpoint of the study, with consistent LDL-C lowering maintained over 78 weeks."These results demonstrated the durable efficacy for Praluent when added to maximally-tolerated statin therapy and further reinforce its generally consistent safety profile," said Jennifer Robinson, M.D., M.P.H., Director of the Prevention Intervention Center, Professor, Departments of Epidemiology & Medicine, College of Public Health at the University of Iowa. "Additionally, the post hoc analysis of major cardiovascular events represents an important finding for Praluent -- we look forward to results from the ongoing ODYSSEY OUTCOMES trial, which is prospectively evaluating the potential of Praluent to reduce cardiovascular events."
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use